Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific; RNA polymerase II cis-regulatory region sequence-specific DNA binding activity; and transcription corepressor binding activity. Predicted to be involved in several processes, including protein phosphorylation; regulation of DNA-templated transcription; and regulation of alpha-beta T cell differentiation. Predicted to act upstream of or within several processes, including chondrocyte differentiation; hair follicle morphogenesis; and positive regulation of extrinsic apoptotic signaling pathway. Predicted to be located in cytosol; nucleolus; and nucleoplasm. Predicted to be part of chromatin. Human ortholog(s) of this gene implicated in several diseases, including breast cancer (multiple); female reproductive organ cancer (multiple); lung non-small cell carcinoma; pancreatic cancer; and urinary bladder cancer. Orthologous to human RUNX3 (RUNX family transcription factor 3); PARTICIPATES IN transforming growth factor-beta Smad dependent signaling pathway; INTERACTS WITH 1-chloro-2,4-dinitrobenzene; 17beta-estradiol 3-benzoate; 2,3,7,8-tetrachlorodibenzodioxine.
[NOG protein co-treated with entinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX3 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1, 3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of RUNX3 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX3 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1, 3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of RUNX3 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1, 3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of RUNX3 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1, 3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of RUNX3 mRNA
[tris(2-butoxyethyl) phosphate co-treated with IMOL S-140 co-treated with tri-(2-chloroisopropyl)phosphate co-treated with tris(1, 3-dichloro-2-propyl)phosphate co-treated with triphenyl phosphate co-treated with santicizer 148 co-treated with tris(chloroethyl)phosphate co-treated with 2-ethylhexyldiphenylphosphate co-treated with tributyl phosphate] results in decreased expression of RUNX3 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1, 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX3 mRNA
DNA copy-number loss on 1p36.1 harboring RUNX3 with promoter hypermethylation and associated loss of RUNX3 expression in liver fluke-associated intrahepatic cholangiocarcinoma.
